# Certara share price today (Certara, Inc., CERT)

> Certara, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CERT · Healthcare · Health Information Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/cert

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $10.87 (−6.5% in a year)
- Revenue (Jun 2026): $93.3 M
- Profit (Jun 2026): −$55.3 M
- Operating margin: −0.2%
- ROE: 0%, FY25
- ROIC: 1.6%, against a 10.2% cost of capital: −8.6 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Certara share price today? Certara, Inc.'s share price was $10.87 at the close on 3 November 2026. That is 49.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $11, and at that close it sat 98% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 19 weeks in a row. Over the last 1 year the share price moved −2% while the S&P 500 moved +21%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Certara pay? Certara, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Certara on? Certara is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Certara profitable? Certara, Inc. posted a net loss of $55.3 M in the Jun 2026 quarter. The full FY25 year was a loss of $1.6 M. That loss is 59.3% of the quarter's revenue. The same quarter a year earlier lost $12.6 M. 7 of the last 8 reported quarters were loss-making. ## How much revenue does Certara make, and is it growing? Certara, Inc. reported $93.3 M of revenue in the Jun 2026 quarter. Over 4 years it has grown 10.0% a year on average. The last full year, FY25, came in at $419 M. The quarterly figures for FY25 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $419 M, +8.7% on the year before. ## How much of every $100 of sales does Certara keep? Certara, Inc.'s operating margin was −0.2% in the Jun 2026 quarter. Across 5 years it has been between 4.3% and 11.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed +3.0 percentage points on the year while gross margin changed +5.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Certara's profit turning into cash? Certara, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $96.3 M of operating cash against −$1.6 M of profit. After $1.8 M of spending on assets, $94.6 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Certara's cash go? Certara, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.2 M on assets over the last 3 years. Averaged over those years that is 0.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.2 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Certara's P/E ratio, and how does it compare with its own history? Certara, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Certara, Inc. at 4.0× its FY25 revenue of $419 M. The P/E comes back here once profit turns positive. ## Is the Certara business getting better or worse? Certara, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Certara earn on its capital? Certara, Inc. earned a ROE of 0% in FY25. That is up from a low of −5% in FY23. Its return on capital used (ROIC) is 8.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −0.4% net margin and 0.27× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −0.4% net margin × 0.27× asset turnover × 1.46× leverage (assets divided by equity) ≈ −0.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 1.6% − 10.2% = −8.6 percentage points. The 10.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 1.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −0.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Certara have too much debt? Certara, Inc. has total debt of $302 M against shareholder equity of $967 M as of Jun 2026, so its debt is 0.31× its equity. Year by year, that ratio went from 0.30 in FY21 to 0.29 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Certara shareholding pattern? 22.9% of Certara, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Certara from balance-sheet trouble? For Certara, Inc., the Z-score is 2.22. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.22 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Certara rank in its industry? 46.4 out of 100, rank 12 of 29 in Health Information Services, with 64% of the evidence available. Certara, Inc. scores 46.4 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 12. Relative strength against the index is 35.7%, and revenue and profit growth are weak. The four parts add up to the total exactly: 12 + 8.2 + 8.6 + 17.6 = 46.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Certara compared with? Certara ranks 12 of 29 Health Information Services companies on the 4-Factor Sector Score, with 46.4 out of 100. 1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) HNGE · leader · Most evidence points up · 64% evidence 72.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 49.7% · Profit n/a · Operating margin change 436.5 points · 62% evidence Capital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidence Valuation 9.3/20 · P/E 59.8× · PEG n/a · 15% evidence Relative strength 17.7/20 · Lead over its industry 42% · Lead over S&P 500 75.7% · 1 year 162.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.5 + 19 + 9.3 + 17.7 = 72.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Veeva Systems Inc.](https://www.sectoralpha.in/us/stocks/veev) VEEV · breaking out · Most evidence points up · 85% evidence 69.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidence Capital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidence Valuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidence Relative strength 16.9/20 · Lead over its industry 6.4% · Lead over S&P 500 33.9% · 1 year 2.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 18.8 + 13 + 16.9 = 69.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) HTFL · leader · Evidence leans up · 61% evidence 57.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 43.2% · Profit n/a · Operating margin change 3.7 points · 62% evidence Capital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.2/20 · Lead over its industry 23.6% · Lead over S&P 500 54.5% · 1 year 67.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 4.5 + 10 + 19.2 = 57.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) WAY · breaking out · Evidence leans up · 81% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidence Capital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidence Valuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidence Relative strength 8.0/20 · Lead over its industry -20.2% · Lead over S&P 500 2% · 1 year -23.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.7 + 12.2 + 15.6 + 8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) SDGR · leader · Evidence leans up · 64% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 8.8% · Profit n/a · Operating margin change 26 points · 62% evidence Capital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidence Valuation 11.2/20 · P/E -22.3× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 22.6% · Lead over S&P 500 53% · 1 year 52.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 4.6 + 11.2 + 18.5 = 55.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) HQY · quiet · Evidence leans up · 85% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidence Capital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidence Valuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidence Relative strength 6.1/20 · Lead over its industry -15.9% · Lead over S&P 500 7.3% · 1 year 8.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.4 + 16.1 + 11.6 + 6.1 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BrightSpring Health Services, Inc.](https://www.sectoralpha.in/us/stocks/btsg) BTSG · turning · Too little evidence to rank firmly · 56% evidence 53.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 39% evidence Capital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidence Valuation 10.0/20 · P/E 39.7× · PEG n/a · 15% evidence Relative strength 11.3/20 · Lead over its industry 2.2% · Lead over S&P 500 29.7% · 1 year 110.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20 + 12.6 + 10 + 11.3 = 53.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. [Doximity, Inc.](https://www.sectoralpha.in/us/stocks/docs) DOCS · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidence Capital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidence Valuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidence Relative strength 9.8/20 · Lead over its industry -17.6% · Lead over S&P 500 5.1% · 1 year -40% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.5 + 20.9 + 10.8 + 9.8 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) TEM · breaking out · Evidence leans up · 64% evidence 51.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.1/35 · Revenue 50.2% · Profit n/a · Operating margin change -0.6 points · 62% evidence Capital efficiency 5.6/25 · ROCE -14.3% · Operating margin -19.6% · 76% evidence Valuation 11.4/20 · P/E -40.9× · PEG n/a · 15% evidence Relative strength 14.4/20 · Lead over its industry -1.4% · Lead over S&P 500 25% · 1 year 8.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.1 + 5.6 + 11.4 + 14.4 = 51.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) PHR · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 12.7% · Profit n/a · Operating margin change 7.2 points · 71% evidence Capital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidence Valuation 9.0/20 · P/E 63.5× · PEG n/a · 15% evidence Relative strength 5.7/20 · Lead over its industry -26.7% · Lead over S&P 500 -6.1% · 1 year -44.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.7 + 9.5 + 9 + 5.7 = 47.9 · What this means: Earnings are strong; relative strength in its sector is -26.7% and the one-year return is -44.5%. 11. [NRC Health](https://www.sectoralpha.in/us/stocks/nrc) NRC · turning · Evidence leans down · 64% evidence 47.7 out of 100 Growth Capital Valuation Relative
12. Certara, Inc. this page CERT · leader · Evidence leans down · 64% evidence 46.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 4.5% · Profit -855.6% · Operating margin change -2.3 points · 62% evidence Capital efficiency 8.2/25 · ROCE 0.8% · Operating margin -0.2% · 76% evidence Valuation 8.6/20 · P/E 180.5× · PEG n/a · 15% evidence Relative strength 17.6/20 · Lead over its industry 7.3% · Lead over S&P 500 35.7% · 1 year 25.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12 + 8.2 + 8.6 + 17.6 = 46.4 · What this means: Relative strength against the index is 35.7%, and revenue and profit growth are weak. 13. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) HSTM · leader · Evidence leans down · 81% evidence 46.2 out of 100 Growth Capital Valuation Relative
14. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) SPOK · turning · Evidence leans down · 81% evidence 46.1 out of 100 Growth Capital Valuation Relative
15. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) AMWL · losing its lead · Evidence leans down · 61% evidence 45.2 out of 100 Growth Capital Valuation Relative
16. [10x Genomics, Inc.](https://www.sectoralpha.in/us/stocks/txg) TXG · leader · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
17. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) OMDA · quiet · Evidence leans down · 64% evidence 44.9 out of 100 Growth Capital Valuation Relative
18. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) PRVA · basing · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
19. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) OMCL · basing · Evidence leans down · 71% evidence 42.7 out of 100 Growth Capital Valuation Relative
20. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) CARL · breaking out · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
21. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) TDOC · turning · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
22. [Claritev Corporation](https://www.sectoralpha.in/us/stocks/ctev) CTEV · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative
23. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) SOPH · losing its lead · Evidence leans down · 61% evidence 37.1 out of 100 Growth Capital Valuation Relative
24. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) EVH · turning · Evidence leans down · 64% evidence 36.9 out of 100 Growth Capital Valuation Relative
25. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) GDRX · quiet · Most evidence points down · 81% evidence 33.9 out of 100 Growth Capital Valuation Relative
26. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) SLP · Too little evidence to rank firmly · 44% evidence 56.3 out of 100 Growth Capital Valuation Relative
27. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) TALK · Too little evidence to rank firmly · 44% evidence 48.4 out of 100 Growth Capital Valuation Relative
28. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) WEAV · Too little evidence to rank firmly · 41% evidence 47.7 out of 100 Growth Capital Valuation Relative
29. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) TBRG · Too little evidence to rank firmly · 31% evidence 42.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Health Information Services](https://www.sectoralpha.in/us/sectors/health-information-services), all 29 compared on one page. ## Which companies are close to Certara in size? Certara is the 12th largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: HeartFlow, Inc., Privia Health Group, Inc. and Schrödinger, Inc. Just below it: Teladoc Health, Inc., Omnicell, Inc. and GoodRx Holdings, Inc. ### Health Information Services companies close in size

1. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) $4.7 billion
2. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) $2.7 billion
3. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) $2 billion
4. Certara, Inc. $1.7 billion
5. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) $1.6 billion
6. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) $1.6 billion
7. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) $1.2 billion

[All 30 Health Information Services companies, largest first](https://www.sectoralpha.in/us/sectors/health-information-services#all-companies)

### Companies close in size in other industries

1. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) $1.6 billion · Medical Devices
2. [Intellia Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ntla) $1.6 billion · Biotechnology
3. Certara, Inc. $1.6 billion
4. [Hillman Solutions Corp.](https://www.sectoralpha.in/us/stocks/hlmn) $1.6 billion · Tools & Accessories
5. [Ingles Markets, Incorporated](https://www.sectoralpha.in/us/stocks/imkta) $1.6 billion · Grocery Stores

## What else do people ask about Certara? ### What were Certara's latest quarterly results? Certara, Inc. reported revenue of $93.3 M and a net loss of $55.3 M for the Jun 2026 quarter. Earnings per share were −$0.36. The operating margin was −0.2% (as of 3 November 2026). ### What is Certara's market cap? Certara, Inc.'s market capitalisation is $1.7 B at a stock price of $10.87. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Certara performing? Certara, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 19 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Certara's stock price go up? This page does not forecast Certara, Inc.'s stock price. What it shows instead: the stock price is $10.87. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Certara in its business cycle? Certara, Inc.'s FY25 operating margin was 5.6%, against a 5-year range of 4.3% to 11.0%: the low end of its own range, which is often where recoveries start. The latest quarter was −0.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Certara story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Certara a stock worth studying right now? What the numbers show: Certara, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.